和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

交易中 09-10 15:37:42

14.270

-0.170

-1.18%

最高14.740	最低13.980	成交量733.20万
今开14.440	昨收14.440	日振幅5.26%
总市值124.01亿	流通市值124.01亿	总股本8.69亿
成交额1.05亿	换手率0.84%	流通股本8.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":14.27,"timestamp":1789025853302,"preClose":14.44,"halted":0,"volume":7332000,"delay":0,"changeRate":-0.011772853185595563,"floatShares":869000000,"shares":869000000,"eps":0.11,"marketStatus":"交易中","change":-0.17,"latestTime":"09-10 15:37:42","open":14.44,"high":14.74,"low":13.98,"amount":104573536,"amplitude":0.052632,"askPrice":14.27,"askSize":16000,"bidPrice":14.24,"bidSize":24000,"shortable":3,"etf":0,"ttmEps":0.762,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789027800000},"marketStatusCode":2,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":14.44,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.462583,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU2580892862.HKD","BK1141","LU2148510915.USD","09926","LU0463099449.HKD","LU1813983027.USD","LU0181495838.USD","LU0516422952.EUR","SG9999004220.SGD","LU0979878070.USD","LU0572944931.SGD","KURE","01801","09995","LU0417516738.SGD","06160","LU1580142542.USD","LU1226287875.USD","LU1794554557.SGD","01093","LU1880383366.USD","LU0348825331.USD","LU2039709279.SGD","06030","06185","LU1226287792.SGD","LU1969619763.USD","02142","02616","BK0028","LU0561508036.HKD","LU1820825898.SGD","LU0405327494.USD","LU1255011170.USD","02269","01177","600030","LU1961090484.USD","LU0819121731.USD","IE0008369823.USD","KCE","01877","LU1064130708.USD","LU1655091616.SGD","09688","LU1997245177.USD","LU0348783233.USD","BK1161","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666295555","title":"和铂医药：BD进入“复利时刻”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666295555","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666295555?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:19","pubTimestamp":1788999594,"startTime":"0","endTime":"0","summary":"中国创新药BD出海正在经历一场质变。","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6581147","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1583","BK1574","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132556829","title":"和铂医药-B旗下Solstice Oncology启动2.25亿美元A轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1132556829","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132556829?lang=zh_cn&edition=full","pubTime":"2026-09-09 23:21","pubTimestamp":1788967293,"startTime":"0","endTime":"0","summary":"9月9日，路透社消息——和铂医药-B（2142.HK）今日公告，其旗下Solstice Oncology正式启动A轮融资，规模高达2.25亿美元。此举标志着该公司在肿瘤治疗领域的战略布局迈出关键一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133473068","title":"和铂医药-B：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并启动运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1133473068","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133473068?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:15","pubTimestamp":1788952531,"startTime":"0","endTime":"0","summary":"2026年9月9日，和铂医药-B发布自愿公告称，其合作伙伴Solstice Oncology已完成2.25亿美元A轮融资并正式启动运营。本轮融资由RA Capital Management领投，Canaan Partners、Forbion及其他投资者共同参与。Solstice Oncology是一家临床阶段的肿瘤免疫公司，专注于新辅助治疗领域，成立于2026年2月。截至本公告日，和铂医药-B董事会成员包括执行董事王劲松博士、陈侑晨先生、刘毅博士，以及独立非执行董事Robert Irwin Kamen博士、叶小平博士、Albert R. Collinson博士和陈维维女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587444","title":"和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587444","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666587444?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:13","pubTimestamp":1788952398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，公司的合作伙伴公司Solstice Oncology 已完成2.25亿美元的A轮融资并正式启动运营。Solstice是一家临床阶段的肿瘤免疫公司，致力于在新辅助治疗阶段更早地干预癌症。MSS型是结肠癌中占比最大的亚型，迄今为止该患者群体仍未能从免疫治疗中获益。该2期临床试验预计将于 2026年第四季度初启动患者入组，并预期将于2027年下半年取得该研究数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136108597","title":"和铂医药合作方Solstice Oncology完成2.25亿美元A轮融资，推进新辅助肿瘤免疫疗法Porustobart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136108597","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136108597?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:13","pubTimestamp":1788952393,"startTime":"0","endTime":"0","summary":"和铂医药的合作伙伴Solstice Oncology宣布，已成功完成2.25亿美元的A轮融资。这笔资金将用于加速其核心候选药物Porustobart的临床开发，该药物定位为新辅助免疫肿瘤学疗法。Solstice Oncology表示，所筹资金将重点投向Porustobart的后续临床试验，旨在探索该药物在早期肿瘤治疗中的应用潜力，以期在手术前缩小肿瘤、改善患者预后。Porustobart作为一种创新免疫疗法，其设计初衷是在标准手术干预前调动患者自身免疫系统对抗肿瘤。Solstice Oncology的此番布局，有望为这一赛道注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539369","title":"和铂医药宣布其合作伙伴Solstice Oncology完成2.25亿美元A轮融资，加速推进新辅助肿瘤免疫疗法普鲁苏拜单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539369","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666539369?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:12","pubTimestamp":1788952320,"startTime":"0","endTime":"0","summary":"普鲁苏拜单抗治疗结肠癌的2期试验将于2026年第四季度初启动患者入组。和铂医药创始人、董事长兼首席执行官王劲松博士表示：\"我们非常高兴看到Solstice Oncology在顶级投资者的有力支持下成功启动运营，并将普鲁苏拜单抗推进至新辅助治疗领域。关于Solstice Oncology Solstice Oncology是一家临床阶段的肿瘤免疫公司，专注于新辅助治疗领域。Solstice成立于2026年2月，核心团队在肿瘤领域拥有数十年成功研发和推进免疫治疗药物的丰富经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5043403_ZH43403_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5043403_ZH43403_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK1161","BK1583","CANC","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187495546","title":"异动解读｜和铂医药-B盘中上涨5.02%，核心管线HBM9378哮喘II期中期数据积极并启动III期","url":"https://stock-news.laohu8.com/highlight/detail?id=1187495546","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187495546?lang=zh_cn&edition=full","pubTime":"2026-09-09 10:38","pubTimestamp":1788921521,"startTime":"0","endTime":"0","summary":"9月9日，和铂医药-B盘中上涨5.02%，报15.23港元，成交额5980.62万港元。消息面上，公司合作伙伴Windward Bio AG于9月8日公布，HBM9378/WIN378在全球Ⅱ/Ⅲ期POLARIS-1临床研究中取得Ⅱ期中期阳性结果，并已正式启动Ⅲ期研究。HBM9378/WIN378为靶向TSLP的全人源超长效单抗，具备双位点结合TSLP的独特机制，药代动力学显示半衰期最长可达75天，支持每年仅需两次给药。此外，公司已于9月7日正式纳入恒生综合指数成份股，预计符合港股通纳入标准，有助于拓宽投资者基础及提升流动性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药盘中上涨，核心管线哮喘II期数据积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666097963","title":"港股异动 | 和铂医药-B(02142)早盘涨超4% 超长效TSLP抗体哮喘II期成功 三期临床已启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2666097963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666097963?lang=zh_cn&edition=full","pubTime":"2026-09-09 10:38","pubTimestamp":1788921514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B早盘涨超4%。截至发稿，涨4.67%，报15.23港元，成交额5980.62万港元。消息面上，9月8日，和铂医药及科伦博泰宣布，其合作伙伴Windward Bio已公布POLARIS-1临床研究II期部分的阳性中期结果。该研究正在评估超长效TSLP双抗HBM9378/WIN378每年两次给药方案治疗哮喘的效果。此外，Windward Bio计划于 2027 年上半年启动第二项三期临床研究POLARIS-2。公司董事会表示，此次获纳入港股通，将为公司引入更广泛的投资者基础，进一步提升股份流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","KCAI","02142","VXUS","BK4588","BK1574","BK4585","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665738153","title":"和铂医药-B(02142)：HBM9378/WIN378治疗哮喘的 II期临床取得阳性的中期结果及III期研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665738153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665738153?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:54","pubTimestamp":1788872083,"startTime":"0","endTime":"0","summary":"HBM9378/WIN378是目前已知唯一一款通过双位点结合TSLP来阻断其信号通路的在研药物，能够干扰TSLP与其两个共受体在上皮细胞表面的结合。该研究亦同时评估HBM9378/WIN378对肺功能和气道炎症生物标志物的影响。其III期部分正在评估两种每年两次给药剂量的HBM9378/WIN378对比安慰剂的疗效，主要终点为重度哮喘患者的年化哮喘急性发作率。HBM9378/WIN378耐受性及安全性良好，截至数据截止日期，未观察到治疗相关严重不良事件、退出或停药。注射部位反应发生率低于1%，抗药物抗体发生率为2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：HBM9378/WIN378治疗哮喘的 II期临床取得阳性的中期结果及III期研究启动","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02142","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118701962","title":"和铂医药-B（02142）披露HBM9378/WIN378治疗哮喘II期中期积极数据并启动III期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1118701962","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118701962?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:45","pubTimestamp":1788871535,"startTime":"0","endTime":"0","summary":"2026年9月8日，和铂医药-B发布自愿公告称，其合作伙伴Windward Bio AG已在全球Ⅱ/Ⅲ期POLARIS-1临床研究中取得HBM9378/WIN378治疗哮喘的Ⅱ期中期阳性结果，并已启动Ⅲ期研究。HBM9378/WIN378为靶向胸腺基质淋巴细胞生成素的全人源超长效单克隆抗体，具备双位点结合TSLP的独特机制，可阻断TSLP与两受体的结合。药代动力学分析显示HBM9378/WIN378半衰期最长可达75天，支持每年两次给药方案。公司提醒投资者，HBM9378/WIN378的最终开发及商业化存在不确定性，请审慎决策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111196658","title":"超长效TSLP靶向抗体HBM9378/WIN378在哮喘2期临床取得积极结果，并启动3期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1111196658","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111196658?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:18","pubTimestamp":1788869898,"startTime":"0","endTime":"0","summary":"聚焦呼吸系统疾病治疗领域的重大突破——和铂医药-B旗下重磅在研产品HBM9378/WIN378，一种针对胸腺基质淋巴细胞生成素的超长效抗体，近日在哮喘适应症的2期临床试验中交出亮眼答卷，数据表现令人振奋。2期临床数据显示，HBM9378/WIN378在控制哮喘症状、改善肺功能等关键指标上均展现出具有临床意义的改善，安全性与耐受性同样可圈可点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665602733","title":"和铂医药-B(02142)：公司股份获纳入沪港通及深港通的股份名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665602733","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665602733?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:17","pubTimestamp":1788740238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，自2026年9月7日起，本公司股份获纳入沪港通及深港通的股份名单，中国内地的合资格投资者可透过沪港通及深港通计划直接投资股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148648525","title":"和铂医药-B（02142）股份确认纳入沪深港通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1148648525","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148648525?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:05","pubTimestamp":1788739530,"startTime":"0","endTime":"0","summary":"2026年9月7日，和铂医药控股有限公司（02142，下称“公司”）发布自愿公告称，自2026年9月7日起，公司股份将被正式纳入沪港通及深港通的股票名单。届时，中国内地的合资格投资者可通过相关互联互通机制直接买卖公司股份。\n公告显示，公司董事会已就此次纳入事宜作出确认，并由公司主席兼执行董事王劲松博士代表董事会发布该公告。\n截至公告日，公司董事会成员包括：执行董事王劲松博士、陈侑晨先生、刘毅博士；独立非执行董事Robert Irwin Kamen博士、叶小平博士、Albert R. Collinson博士及陈维维女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112345622","title":"和铂医药-B更新2026年8月股份变动月报表，增发12.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112345622","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112345622?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:16","pubTimestamp":1788520613,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年9月4日披露截至2026年8月31日的股份变动月报表。报告期末，公司已发行普通股数量由上月底的869,142,522股增至869,264,522股，库藏股数量维持在31,834,000股，总发行股份由900,976,522股微增至901,098,522股。公司在公告中声明，其所有当月的证券发行及库存股份变动均已获得公司董事会正式授权并遵守香港联合交易所有限公司《上市规则》及相关法律规定。公告由执行董事王劲松签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185848751","title":"异动解读｜和铂医药-B盘中上涨5.21%，上半年收入同比增超两成叠加恒生综合指数纳入在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1185848751","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185848751?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:50","pubTimestamp":1788418243,"startTime":"0","endTime":"0","summary":"9月3日，和铂医药-B盘中上涨5.21%，报15.15港元，成交额1.23亿港元，延续前一交易日反弹势头。消息面上，公司此前披露中期业绩，上半年收入1.22亿美元，同比增长20.9%，分子授权及合作收入由9370万美元增至1.13亿美元，中金研报指出业绩超预期，主因CTLA-4海外授权增厚收入，持续BD验证平台价值。此外，公司将于9月7日正式纳入恒生综合指数成份股，届时股份预计符合沪港通及深港通交易纳入标准，增量资金预期升温，叠加此前连续下挫后的超跌修复需求，共同推动股价走强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药盘中拉升，恒指纳入在即","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882101","title":"港股异动 | 和铂医药-B(02142)涨超4% 上半年收入同比增超两成 持续BD验证公司平台价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882101","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882101?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:38","pubTimestamp":1788417512,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B涨超4%，截至发稿，涨4.31%，报15.02港元，成交额1.15亿港元。消息面上，近日，和铂医药-B发布截至2026年6月30日止6个月中期业绩，收入1.22亿美元，同比增长20.9%。公告称，于报告期内，收入总额为1.22亿美元，相较于2025年上半年度1.01亿美元增长20.9%。中金研报指出，和铂医药-B上半年业绩超该行预期，主因CTLA-4海外授权增厚收入。持续BD验证公司的平台价值，但合作收入占比仍超过九成，业绩可能随交易及收入确认节奏波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","BK4585","02142","BK1161","BK1574","BK1583","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664094821","title":"港股异动 | 和铂医药-B(02142.HK)涨超4% 上半年收入同比增超两成 持续BD验证公司平台价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2664094821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664094821?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:38","pubTimestamp":1788417512,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817023","title":"和铂医药：披露戎一平辞任具体缘由","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817023","media":"GPLP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664817023?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:41","pubTimestamp":1788356460,"startTime":"0","endTime":"0","summary":"9月2日，和铂医药发布补充公告，对8月27日披露的董事及授权代表人事变动作出进一步说明。公告明确，戎一平博士辞任执行董事，是希望投入更多时间精力处理自身其他商业事务。回顾此前公告，相关人事变动8月27日生效：戎一平博士辞任执行董事，同时不再担任港交所上市规则3.05条项下授权代表；陈侑晨、刘毅获委任为执行董事，陈侑晨接替出任授权代表。戎一平此前确认，其与董事会不存在意见分歧，无其他事项提请股东及港交所关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-02/doc-iniqnaws2682986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118290967","title":"和铂医药控股有限公司（02142）发布补充公告 说明执行董事辞任原因","url":"https://stock-news.laohu8.com/highlight/detail?id=1118290967","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118290967?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:36","pubTimestamp":1788338204,"startTime":"0","endTime":"0","summary":"2026年9月2日，和铂医药控股有限公司刊发补充公告，进一步说明有关董事会人事变动的最新情况。公司确认，戎一平博士自2026年8月27日起辞去执行董事职务，辞任原因系其希望投入更多时间与精力处理其他商业事务。此前，公司已于2026年8月27日发布公告，披露了执行董事辞任、委任新任执行董事及授权代表变更等事项。公司表示，本补充公告应与2026年8月27日的原公告一并阅读，以便全面了解相关人事调整的具体内容。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.013},{"period":"3month","weight":0.4556},{"period":"6month","weight":0.2033},{"period":"1year","weight":-0.158},{"period":"ytd","weight":0.1875}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0255},{"period":"3month","weight":0.0423},{"period":"6month","weight":-0.0075},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.053076},{"month":8,"riseRate":0.333333,"avgChangeRate":0.031233},{"month":9,"riseRate":0.5,"avgChangeRate":-0.051002},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}